The FDA has suspended the licensing of a chikungunya vaccine, citing safety concerns. The vaccine, which is made by Valneva, is being withdrawn from the US market, with its use halted, particularly in older adults. The suspension of the chikungunya vaccine license has been reported, although the specifics of the safety concerns and the full scope of the suspension are not detailed.